NIH awards $4.6M for trial of skin substitute

Madison, Wis.-based Stratatech received a $4.6 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to test safety and efficacy of the company's ExpressGraft antimicrobial skin substitute in patients with chronic diabetic foot ulcers. The genetically engineered cell-based product fights infection and accelerates healing, according to Stratatech.

View Full Article in:

Milwaukee Journal Sentinel (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID